Nektar Therapeutics Overview
Pro stress-test →Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. The company's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus.
Strategic Profile
Pro stress-test →In February 2026, Nektar announced a $300 million underwritten public offering of common stock and pre-funded warrants, with proceeds intended for research and development, clinical development including Phase 3 trials for rezpegaldesleukin, and manufacturing costs. The company announced in February 2026 an academic research collaboration with UCSF for NKTR-0165, a novel, first-in-class tumor necrosis factor receptor 2 (TNFR2) agonist antibody.
Competitive Landscape
Pro stress-test →Nektar operates in the competitive autoimmune and immunotherapy space. Dupixent (dupilumab) holds well-established commercial dominance in atopic dermatitis, presenting a significant competitive challenge. The company also competes with broader immunology players developing IL-17/23 inhibitors and other checkpoint inhibitors in oncology, though its Treg-stimulating and TNFR2-agonist approaches represent differentiated mechanisms.
Industry Context
Nektar Therapeutics operates in Immunotherapy & Autoimmune Therapeutics.
Key facts
Founded: N/A · Headquarters: San Francisco, US · Employees: N/A · Revenue: N/A · Market cap: N/A